Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.
Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies.
The company had discovery programs that are either completed, in progress, or under contract with partners.
It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.
The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 13, 24 | -0.14 Increased by 0.00% | -0.17 Increased by +17.65% |
| Feb 20, 24 | -0.17 Decreased by -70.00% | -0.13 Decreased by -30.77% |
| Nov 2, 23 | -0.10 Decreased by -225.00% | -0.13 Increased by +23.08% |
| Aug 3, 23 | -0.11 Decreased by -450.00% | -0.13 Increased by +15.38% |
| May 4, 23 | -0.14 Decreased by -125.93% | -0.14 |
| Feb 21, 23 | -0.10 Decreased by -152.63% | -0.01 Decreased by -900.00% |
| Nov 8, 22 | 0.08 Increased by +200.00% | 0.05 Increased by +60.00% |
| Aug 9, 22 | -0.02 Decreased by -100.00% | -0.02 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 6.60 M Decreased by -93.49% | -28.61 M Decreased by -207.46% | Decreased by -433.55% Decreased by -1.75 K% |
| Jun 30, 23 | 10.06 M Decreased by -78.10% | -30.53 M Decreased by -349.93% | Decreased by -303.58% Decreased by -1.95 K% |
| Mar 31, 23 | 12.19 M Decreased by -96.15% | -40.11 M Decreased by -123.79% | Decreased by -328.99% Decreased by -717.84% |
| Dec 31, 22 | 21.55 M Decreased by -84.54% | -29.89 M Decreased by -149.86% | Decreased by -138.75% Decreased by -422.48% |
| Sep 30, 22 | 101.38 M Increased by +1.74 K% | 26.62 M Increased by +224.53% | Increased by +26.26% Increased by +106.77% |
| Jun 30, 22 | 45.92 M Increased by +66.11% | -6.79 M Decreased by -192.08% | Decreased by -14.78% Decreased by -75.84% |
| Mar 31, 22 | 316.58 M Increased by +56.15% | 168.57 M Increased by +43.81% | Increased by +53.25% Decreased by -7.90% |
| Dec 31, 21 | 139.33 M Decreased by -32.98% | 59.95 M Decreased by -48.76% | Increased by +43.03% Decreased by -23.54% |